Dr. Weintraub's approach emphasizes collaboration and tailored treatment plans, ensuring patients receive the best possible care suited to their unique needs. He specializes in managing patients with a wide range of endocrine conditions, including obesity, diabetes, osteoporosis, and disorders of the thyroid, adrenal, and pituitary.
His particular interest lies in obesity medicine, a dynamic field that offers increasingly effective tools for treating and preventing weight gain, which is often the root cause of many chronic diseases. By working closely with nutritionists, surgeons, and other specialists, he strives to deliver holistic and effective care.
In addition to caring for patients, Dr. Weintraub is passionate about academic medicine, research, and training the next generation of physicians. He co-chairs the pharmacologic management of obesity guideline update through the Endocrine Society and serves on the exam writing committee for the American Board of Obesity Medicine. He is actively involved in clinical research within endocrinology and obesity medicine.
| Fellowship: Endocrinology, Diabetes & Metabolism |
Cornell New York Presbyterian Hospital
Memorial Sloan Kettering Cancer Center
|
| Residency: Internal Medicine |
Thomas Jefferson University Hospital
|
| Medical School |
Rutgers Robert Wood Johnson Medical School
|
| Undergraduate |
University of Pennsylvania
The Wharton School
|
NEJM Course Faculty Director
Faculty Director for the New England Journal of Medicine Group's "Advancing Obesity Care" course, collaborating with leading experts to deliver evidence-based approaches for obesity management and GLP-1 therapies.
Learn More
Endocrine Society Guidelines Co-Chair
Co-Chair of the pharmacologic management of obesity guideline update through the Endocrine Society, leading the development of evidence-based recommendations for obesity pharmacotherapy.
Learn More
American Board of Obesity Medicine
Serving on the exam writing committee for the American Board of Obesity Medicine, contributing to the certification and education of obesity medicine specialists nationwide.
Learn MoreFeatured expert discussing compounded obesity medications, addressing regulatory considerations, safety, efficacy, and patient access concerns in the evolving landscape of obesity pharmacotherapy.
Listen NowExpert commentary on how the European Association for the Study of Obesity framework reshapes clinical practice by moving beyond BMI to focus on individualized, health-centered approaches.
Watch VideoDiscussing real-world data presented at ObesityWeek on weight regain patterns after GLP-1 discontinuation and implications for long-term obesity management strategies.
Read ArticlePresented real-world evidence on weight regain after GLP-1 discontinuation, highlighting the chronic nature of obesity and the importance of continuous treatment strategies.
View DetailsLecturer for the Columbia Cornell intensive CME program covering evidence-based approaches to obesity etiology, prevention, and treatment. Course emphasizes practical pharmacologic, nutritional, behavioral, and procedural interventions for patient-centered care.
Course InformationRegular speaker on obesity medicine topics including GLP-1 therapies, metabolic complications, and evidence-based treatment approaches.
Connect
NYU Langone Diabetes & Endocrine Associates
222 East 41st Street, 23rd Floor
New York, NY 10017
I actively share research insights, clinical commentary, and updates on obesity medicine and GLP-1 therapies across professional platforms.
Real-world study reveals significant variation in GLP-1 treatment outcomes: 42.9% of European adults with type 2 diabetes failed to achieve clinically meaningful improvements in glycemic control or weight. Only 14% achieved meaningful reductions in both A1C and body weight, highlighting the substantial unmet need in diabetes management.
Read Full PostPost-hoc analysis from US Diabetes Prevention Program and China DaQing study reveals prediabetes remission achieved through intensive lifestyle intervention leads to 59% lower risk of cardiovascular death or heart failure hospitalization. Remission provided benefits beyond weight loss alone, with greater improvements in insulin sensitivity and reductions in visceral adipose tissue.
View ThreadHonored to serve as Faculty Director for the New England Journal of Medicine's new course on obesity management. Collaborating with leading experts to deliver evidence-based approaches for GLP-1 therapies, individualized treatment strategies, and health equity. Free CME credits available for healthcare professionals.
Read Full PostFirst phase 3 trial of retatrutide (triple GLP-1/GIP/glucagon agonist) shows remarkable 28.7% weight loss at 68 weeks in patients with obesity and osteoarthritis. Trial demonstrated significant improvements in cardiometabolic markers, 14 mmHg systolic BP reduction, and 75.8% reduction in WOMAC pain scores with improved physical function.
View ThreadJoin me for regular insights on obesity medicine, GLP-1 research, and endocrinology
